Jay Suman Raval MD
Blood Banking & Transfusion Medicine
Professor, Department of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont
Join to View Full Profile
89 Beaumont AvenueCourtyard at Given S269Burlington, VT 05405
Dr. Raval is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jay Raval is a pathologist at the Robert Larner, M.D. College of Medicine at the University of Vermont. He received his medical degree from University of North Carolina at Chapel Hill School of Medicine, received post-graduate training at the University of Pittsburgh Medical Center (UPMC), and has been in practice for 15 years. He specializes in blood banking, transfusion medicine, apheresis medicine, and cellular therapies.
Education & Training
UPMC Medical Education/Institute for Transfusion MedicineFellowship, Blood Banking/Transfusion Medicine, 2010 - 2011- UPMC Medical EducationResidency, Pathology-Anatomic and Clinical, 2007 - 2010
- UPMC Medical Education (Pittsburgh)Residency, Surgery, 2006 - 2007
University of North Carolina at Chapel Hill School of MedicineClass of 2006
Certifications & Licensure
VT State Medical License 2024 - 2026
NM State Medical License 2018 - 2025
NC State Medical License 2012 - 2020
PA State Medical License 2009 - 2012
American Board of Pathology Pathology - Clinical- American Board of Pathology Blood Banking/Transfusion Medicine
Publications & Presentations
PubMed
- Use of an anti-D-alloimmunization kinetics model to correct the interval censored D-alloimmunization rate following red blood cell transfusions.Emil Ainsworth Jochumsen, Kathleen Selleng, Jay S Raval, Carolina Bonet Bub, Jose M Kutner
Transfusion. 2025-05-01 - A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Dis...Jeremy W Jacobs, Brian D Adkins, Garrett S Booth, Caroline G Stanek, Elizabeth S Allen
Journal of Clinical Apheresis. 2025-04-01 - Why do people still make anti-D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study.Regina M DelBaugh, Michael F Murphy, Julie Staves, Roberta Maria Fachini, Silvano Wendel
Transfusion. 2025-03-10
Journal Articles
- ADAMTS13: Origins, Applications, and ProspectsBrian S Zuckerbraun, Matthew D Neal, Jay S Raval, Mitchell R Dyer, Transfusion
Abstracts/Posters
- African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic PurpuraJay S Raval, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic InjuryJay S Raval, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian PopulationsJay S Raval, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
